ImmunityBio, Inc.

Aug 10, 2026

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

ImmunityBio, Inc. has appointed Dr. Jim Yong Kim as Vice Chairman, a newly created role. Dr. Kim will focus on enhancing the company's global relationships and will report to Executive Chairman Dr. Patrick Soon-Shiong. This strategic move aims to leverage Dr. Kim's extensive experience in global health.

Aug 4, 2026

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

ImmunityBio, Inc. reported a record net product revenue of $50.7 million for Q2 2026, marking a 92% increase compared to the previous year and a 15% rise from the first quarter of 2026. The company also made significant progress in its immunotherapy pipeline, achieving its eighth consecutive quarter of growth. Overall, the financial results reflect strong operational performance.

Jul 29, 2026

▲ +9.1%on this newsshared move

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

ImmunityBio has received marketing authorization from the Emirates Drug Establishment for its product ANKTIVA across two cancer indications. The approval allows for the use of ANKTIVA in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and metastatic non-small cell lung cancer (NSCLC). This marks a significant milestone for the company in expanding its market presence in the UAE.

Jun 1, 2026

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

ImmunityBio presented new clinical and comparative data related to lung and bladder cancer at ASCO 2026. The details of the findings were not disclosed in the provided text. The presentation aimed to showcase advancements in treatment options for these cancers. Further insights into the data are anticipated from the conference.

May 22, 2026

▼ -6.7%on this news

ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation

ImmunityBio presented patient survey data at ISPOR 2026, revealing that most UK adults living with non-muscle invasive bladder cancer (NMIBC) prefer bladder preservation strategies. This finding underscores the importance of patient preferences in treatment decisions. The data reflects a shift towards more patient-centered approaches in managing NMIBC.

May 22, 2026

▼ -6.7%on this news

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

ImmunityBio presented a health economic analysis at ISPOR 2026, highlighting that ANKTIVA® combined with BCG offers a lower cost per sustained complete response compared to TAR-200 for patients with BCG-unresponsive NMIBC CIS. This analysis may influence treatment decisions in the management of bladder cancer.

May 20, 2026

ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027

ImmunityBio has announced that the FDA has accepted its supplemental Biologics License Application (BLA) for ANKTIVA® in combination with BCG for the treatment of BCG-unresponsive non-muscle invasive bladder cancer with papillary disease. The FDA has set a Prescription Drug User Fee Act (PDUFA) date for January 6, 2027, marking a key regulatory milestone for the company.

May 19, 2026

ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026

ImmunityBio presented data comparing the effectiveness of NAI + BCG against Nadofaragene and TAR-200 at AUA 2026. The results focused on complete response rates, but specific details about the findings were not disclosed in the article. The presentation highlights ongoing research in bladder cancer therapies.

May 18, 2026

ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035

ImmunityBio has announced the granting of comprehensive U.S. patents that cover the combination of its product ANKTIVA with BCG for cancer treatment. This patent protection is set to last until 2035, potentially providing a significant competitive advantage in the oncology market. The announcement highlights ImmunityBio's commitment to advancing cancer therapies.

May 16, 2026

IBRX1. Phases

ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States Positive Phase III readout of National Cancer Institute sponsored SWOG S1602 ran

ImmunityBio has entered into an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory for the Tokyo strain of BCG, enhancing BCG availability in the United States. This agreement follows positive Phase III results demonstrating the non-inferiority of Tokyo-172 compared to standard treatments. ImmunityBio plans to pursue FDA approval for the Tokyo strain, while continuing its partnership with Serum Institute of India for additional supply options. This development addresses long-standing BCG shortages faced by urologists and their patients in the U.S.

ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million

ImmunityBio reported impressive financial results for Q1 2026, with net product revenue reaching approximately $44.2 million, marking a 168% increase compared to Q1 2025. This growth reflects a consistent upward trend since the commercial launch of ANKTIVA. The company also reported a robust cash position of $381 million.

May 5, 2026

ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting

ImmunityBio is set to present new comparative data and scientific advancements related to non-muscle invasive bladder cancer at the upcoming American Urological Association Annual Meeting. The presentation will also include an update on their BCG Naïve Registrational Trial. This event is expected to highlight the company's contributions to bladder cancer research.

Apr 30, 2026

IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug Capabilities - ImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallSt

A class action lawsuit has been filed against ImmunityBio, Inc. (IBRX) alleging that the company made false and misleading statements regarding its drug ANKTIVA. The lawsuit follows a significant stock decline after an FDA Warning Letter indicated that the company's promotional claims were misleading. Investors who purchased shares during the specified period may be eligible for compensation.

Apr 21, 2026

ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership

ImmunityBio has announced the commercial availability of ANKTIVA® in Saudi Arabia for bladder and lung cancer patients. The entry into the market was accomplished within just two months following a partnership in the MENA region. The drug will be used in combination with BCG for treating specific cancer indications.

Apr 10, 2026

ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

ImmunityBio reported a significant increase in net product revenue for Q1 2026, reaching approximately $44.2 million, a 168% rise from Q1 2025. The company has seen consistent revenue growth since the launch of ANKTIVA, which is now approved in 34 countries. With $380.9 million in cash and marketable securities, ImmunityBio is focused on expanding its market presence and advancing its clinical pipeline.

Apr 9, 2026

▲ +7.2%on this newsshared move

ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

ImmunityBio, Inc. reported a remarkable increase in net product revenue for Q1 2026, reaching approximately $44.2 million, which is a 168% growth compared to Q1 2025. This growth marks a continuous upward trend since the commercial launch of their product ANKTIVA. The company also reported having $381 million in cash and marketable securities.

Apr 6, 2026

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance Company initiated a comprehensive review of promotional materials and is implementing enhanced advertising complian

ImmunityBio, Inc. has responded to concerns raised by the FDA regarding its advertising practices, specifically related to a podcast and an unbroadcast television advertisement. The company has committed to enhancing its compliance processes and ensuring that all promotional communications for its therapy ANKTIVA adhere to FDA regulations. ImmunityBio has implemented corrective actions including the removal of problematic content and training for executives. The company aims to maintain clarity in its communications regarding investigational drugs and approved therapies.

Apr 6, 2026

ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance

ImmunityBio has responded to recent correspondence from the FDA regarding its advertising practices. The company has reaffirmed its commitment to compliance with advertising regulations. Further details on the specific nature of the correspondence were not disclosed in the article.

Mar 31, 2026

▲ +15.2%on this newsshared move

ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline

ImmunityBio has successfully secured $100 million in financing, which includes $75 million in non-dilutive funding. This financing is intended to support the company's global expansion and further advancement of its immunotherapy pipeline following recent regulatory approvals. The company aims to enhance its commercial efforts, particularly with the immunotherapy drug ANKTIVA, which has received approval in 34 countries. These developments reflect ImmunityBio's increasing capacity to scale operations and develop next-generation therapies.

Mar 27, 2026

ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026

ImmunityBio announced that its QUILT-2.005 trial is adequately powered to detect clinically meaningful differences in complete response rates between ANKTIVA plus BCG and BCG alone for BCG-naïve NMIBC patients. The Independent Data Monitoring Committee confirmed that no additional enrollment is needed, and a supplemental BLA submission is anticipated for 2026. The trial's results suggest promising durability in patient responses.

Mar 23, 2026

▲ +11%on this newsshared move

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

ImmunityBio has announced that ANKTIVA has received regulatory approval in Macau for treating BCG-unresponsive non-muscle invasive bladder cancer. This marks the drug's first authorization in Asia, aligning with its approved use in the U.S. The approval follows a review of prior regulatory decisions by the FDA and EMA, highlighting the strength of the clinical data supporting ANKTIVA.

Mar 17, 2026

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

ImmunityBio announced that the NCCN has updated its guidelines to include ANKTIVA in combination with BCG for patients with BCG-unresponsive NMIBC with papillary-only disease. This marks a significant expansion of treatment options for patients who have exhausted standard therapies. The update is based on emerging clinical data and aims to enhance patient care in bladder cancer management.

Mar 13, 2026

▲ +7.3%on this newsshared move

ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors

ImmunityBio has successfully completed large-scale production and cryopreservation of natural killer (NK) cells from over 60 donors, establishing a scalable manufacturing pathway for its M-ceNK cell therapy. The Phase I trial combining M-ceNK with ANKTIVA showed safety and potential efficacy in patients with relapsed tumors. No serious adverse events were reported, and the therapy demonstrated significant antitumor activity in preclinical models.

Mar 9, 2026

ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data

ImmunityBio has resubmitted its supplemental Biologics License Application (sBLA) for ANKTIVA combined with BCG for treating BCG-unresponsive NMIBC with papillary tumors. This follows FDA's request for additional data, which ImmunityBio provided. The resubmission includes updated long-term follow-up data, demonstrating significant efficacy and safety results published in The Journal of Urology.

Feb 27, 2026

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

ImmunityBio, Inc. will host a live conference call on March 3, 2026, to discuss business updates and financial results for FY 2025. The call will cover progress in their clinical trial pipeline and will be accessible via their Investor Relations website or by phone. A replay will be available for 90 days post-event.

Feb 26, 2026

ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio has completed enrollment in its Phase 2 trial evaluating ANKTIVA plus BCG for treating BCG-naïve non-muscle invasive bladder cancer. The interim analysis showed significant improvement in complete response duration compared to BCG alone, with no safety concerns. The company plans to submit a biologics license application to the FDA by Q4 2026.

Feb 24, 2026

▲ +17.5%on this newsshared move

ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation “Cancer 2035: A Roadmap for the Future” Summit

Dr. Patrick Soon-Shiong, founder of ImmunityBio, will speak at the 'Cancer 2035: A Roadmap for the Future' summit in Washington, D.C. The event, co-hosted by the Milken Institute and the Richard Nixon Foundation, aims to unite leaders in oncology to discuss strategies for reducing cancer mortality by 2035. The summit will feature discussions on innovative approaches to cancer treatment and prevention.

Feb 23, 2026

▲ +13%on this news· ran to +33% by day 1shared move

ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally

ImmunityBio reported a remarkable 700% year-over-year revenue growth for ANKTIVA, reaching approximately $113 million in net product revenue for 2025. The company has expanded its regulatory approvals for ANKTIVA to include lung cancer, with plans for further global expansion. Despite the positive financial results, ImmunityBio continues to face significant net losses and rising R&D expenses.

Feb 20, 2026

ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

ImmunityBio has partnered with Biopharma and Cigalah Healthcare to launch ANKTIVA in Saudi Arabia for bladder and lung cancer patients. This collaboration aims to enhance access to innovative therapies in the MENA region, addressing significant unmet medical needs. ANKTIVA has received regulatory approvals in various regions, including the U.S. and Saudi Arabia, for specific cancer indications.

Feb 18, 2026

▲ +41.9%on this news· ran to +63% by day 3shared move

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

ImmunityBio has received conditional marketing authorization from the European Commission for ANKTIVA in combination with BCG, targeting BCG-unresponsive non-muscle invasive bladder cancer. This marks a significant advancement as it is the first authorized treatment for this indication in Europe. The approval allows for access in 33 countries, following a strong clinical response rate observed in trials.

Feb 17, 2026

ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia

ImmunityBio reported productive regulatory discussions with the Saudi Food and Drug Authority (SFDA) during the Saudi-USA Biotech Alliance meeting. The SFDA encouraged the submission of a regulatory package for ImmunityBio's recombinant BCG (rBCG) to address a global shortage. Additionally, discussions began regarding the expansion of ANKTIVA in combination with checkpoint inhibitors for various tumor types.

Feb 2, 2026

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

ImmunityBio has launched a Phase 2 trial for ResQ215B, a chemotherapy-free CAR-NK cell therapy targeting indolent B-cell non-Hodgkin lymphoma. This study combines CD19-targeted NK cell therapy with the IL-15 superagonist ANKTIVA and rituximab. Initial results from prior studies indicate promising disease control without significant toxicities, aiming to improve treatment outcomes for patients.

Jan 26, 2026

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

ImmunityBio has reported promising Phase 2 results for its ANKTIVA® therapy combined with CAR-NK in patients with recurrent glioblastoma. The study shows that 19 out of 23 patients are still alive, with median overall survival not yet reached. Additionally, the therapy appears to reverse lymphopenia, a common issue in this patient population. The findings highlight a potential shift in treatment strategies for glioblastoma, aiming to improve patient outcomes without chemotherapy.

Jan 20, 2026

▲ +17.4%on this newsshared move

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

ImmunityBio has engaged in discussions with the FDA regarding the resubmission of its supplemental Biologics License Application for ANKTIVA in treating BCG-unresponsive papillary bladder cancer. The FDA has requested additional information to support the application, which ImmunityBio plans to submit within 30 days. The therapy shows promising survival rates and could provide a much-needed treatment option for patients.

Jan 16, 2026

▲ +39.7%on this news· ran to +86% by day 3shared move

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

ImmunityBio has reported that enrollment in its QUILT-2.005 trial for BCG-naïve NMIBC has surpassed expectations, reaching over 85% completion. An interim analysis indicated that ANKTIVA combined with BCG significantly improves the duration of complete response compared to BCG alone. The company plans to submit a biologics license application to the FDA by the end of 2026.

Jan 16, 2026

▲ +39.7%on this news· ran to +86% by day 3shared move

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

ImmunityBio announced promising results from its QUILT-106 clinical study, showcasing a chemotherapy-free CD19 CAR-NK cell therapy for Waldenström lymphoma. Patients exhibited durable complete responses, with some maintaining remission for up to 15 months. The therapy demonstrated 100% disease control and was administered entirely in an outpatient setting, highlighting its potential as a next-generation treatment.

Jan 16, 2026

▲ +39.7%on this news· ran to +86% by day 3shared move

ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year

ImmunityBio reported a preliminary net product revenue of approximately $38.3 million for Q4 2025, marking a 700% increase year-over-year. The company experienced a 54% growth in unit volume during FY 2025, driven by the adoption of its product ANKTIVA. Additionally, the approval of ANKTIVA in Saudi Arabia is expected to further boost sales momentum. The company ended the quarter with $242.8 million in cash and equivalents.

Jan 15, 2026

▲ +30.8%on this news· ran to +129% by day 3shared move

Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ

ImmunityBio's ANKTIVA has received accelerated approval from the Saudi FDA for treating adults with BCG-unresponsive non-muscle invasive bladder cancer. This approval complements existing authorizations in the U.S., U.K., and EU. The company aims to enhance patient access in the Middle East and North Africa by establishing a regional office and collaborating with local partners.

Jan 14, 2026

▲ +7.1%on this news· ran to +130% by day 3shared move

Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer

ImmunityBio has received accelerated approval from the Saudi FDA for ANKTIVA in combination with checkpoint inhibitors for treating metastatic non-small cell lung cancer. This marks the first global approval for this innovative therapy, which aims to improve patient outcomes in a region with high lung cancer prevalence. The company plans to expand its operations in Saudi Arabia to support healthcare providers and enhance access to this treatment.

Jan 14, 2026

▲ +7.1%on this news· ran to +130% by day 3shared move

ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer

ImmunityBio announced positive results from its ANKTIVA clinical program for non-small cell lung cancer, demonstrating significant immune restoration and improved survival in patients who had previously undergone checkpoint therapy. The studies, QUILT-2.023 and QUILT-3.055, suggest that combining ANKTIVA with checkpoint inhibitors could enhance treatment outcomes. Detailed results are set for peer-review publication.

Jan 13, 2026

▲ +8.9%on this news· ran to +113% by day 3shared move

NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security

NantWorks and ImmunityBio announced the inaugural U.S.-Saudi Biotech Alliance Summit, scheduled for January 14, 2026, during the J.P. Morgan Healthcare Conference. The summit aims to foster collaboration between U.S. and Saudi leaders in biotechnology and healthcare to accelerate the development of immunotherapies. Key topics will include regulatory alignment and health security preparedness.

Dec 31, 2025

ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue-a 700% increase year-over-year ANKTIVA sales momentum continues to trend upward with full year preliminary n

ImmunityBio reported preliminary net product revenue for 2025 of approximately $113 million, a staggering 700% increase year-over-year. The growth was driven by strong sales of ANKTIVA, with unit sales volume rising by 750% compared to 2024. Recent approvals of ANKTIVA in Saudi Arabia for both metastatic non-small cell lung cancer and bladder cancer further bolster the company's market position. Additionally, the ongoing Phase 2b trial of ANKTIVA plus BCG is on track for full enrollment in 2026, suggesting continued progress in clinical development.

Dec 29, 2025

ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”

ImmunityBio announced that Dr. Patrick Soon-Shiong has been recognized by OncoDaily as one of the '100 Most Influential People in Oncology in 2025.' This honor reflects his extensive contributions to cancer research and patient care. Soon-Shiong's leadership is seen as pivotal in driving ImmunityBio's mission to develop transformative therapies for cancer and other serious diseases.

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ-A First in Europe ANKTIVA plus BCG

ImmunityBio has received a positive conditional marketing authorization recommendation from the European Medicines Agency for ANKTIVA in combination with BCG, targeting non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. This marks a significant development as it is the first approved immunotherapy for this condition in Europe. The EMA's decision is influenced by promising clinical trial results showcasing a high complete response rate. Following this recommendation, the European Commission will review the proposal for final marketing authorization across the EU.

Nov 5, 2025

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024 Q3 2025 Revenue and Other Income Growth with Continued Strong Sales Momentum $33.7 mi

ImmunityBio reported a remarkable 467% year-to-date unit growth and $75 million in sales, up 434% from the previous year's comparable quarter. The company highlighted promising early clinical results in glioblastoma, prompting the initiation of a new registration trial. Additionally, ImmunityBio's substantial cash reserves have increased to $257.8 million as of September 30, 2025, providing a solid financial footing. Despite these achievements, the company continues to report significant net losses attributable to common stockholders, underscoring the inherent challenges within its operational costs and overall financial health.

Aug 8, 2025

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA IN RE IMMUNITYBIO, INC. SHAREHOLDER DERIVATIVE LITIGATION NOTICE OF PROPOSED DERIVATIVE SETTLEMENT Lead Case No.: 3:24-cv-02014-GPC-VET (Consolidated with 3:25

ImmunityBio, Inc. is facing a proposed settlement regarding shareholder derivative litigation led by plaintiffs alleging governance failures and misleading disclosures by company executives. The proposed settlement, articulated in court documents, seeks to resolve allegations of fiduciary breaches connected to the company's product, Anktiva, and its regulatory applications. A hearing to discuss the terms of this settlement and determine its fairness to current shareholders is scheduled for November 4, 2025. This litigation has significant implications for the company and its shareholders if the settlement is approved.

Aug 5, 2025

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 million and 246% Unit Growth Since J-code Q2 2025 Revenue Growth with Continued Strong Sales Momentum

ImmunityBio reported strong financial performance for Q2 2025, marking a 60% increase in revenue compared to Q1 2025, totaling $26.4 million. The company achieved a remarkable 246% growth in unit sales since the approval of J-code, showcasing robust commercial traction for its product ANKTIVA. Furthermore, they have launched important clinical trials, including a randomized controlled trial for lung cancer, and received favorable feedback from FDA regarding their lymphopenia program. However, the company expressed concerns over FDA's refusal to file a supplemental BLA based on previous study data requirements.

Jul 25, 2025

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

ImmunityBio, Inc. reported a significant 60% revenue increase in Q2 2025, raising total sales for the year to date to $43 million, supported by 246% growth in unit volume since the J-code approval. The company also achieved progress in its clinical pipeline, particularly with its therapy ANKTIVA for treating non-muscle invasive bladder cancer. However, it faced regulatory challenges, receiving a Refuse-to-File notice from the FDA regarding a supplemental BLA that may require a randomized controlled trial to proceed. Despite these hurdles, ImmunityBio maintains a solid cash position of $153.7 million for ongoing operations.

May 12, 2025

▲ +14%on this news· ran to +29% by day 3

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code For the three months ended

ImmunityBio reported a substantial increase in net revenue and unit sales for the first quarter of 2025, attributing these gains to the recent approval of a permanent J-code that has streamlined billing for providers. The company achieved approximately $16.5 million in net product revenue, representing a 129% increase over the prior quarter, and unit sales of ANKTIVA grew by 150%. However, despite these positive trends in revenue and unit sales, ImmunityBio also reported a significant net loss, highlighting ongoing financial challenges.

IMMUNITYBIO REQUESTS AN URGENT MEETING WITH FDA TO ADDRESS THE CHANGE IN THE AGENCY S UNAMBIGUOUS GUIDANCE ON JAN 2025 TO SUBMIT A sBLA FOR NMIBC BCG UNRESPONSIVE PAPILLARY DISEASE, FOLLOWING AN INCONSISTENT REFUSAL TO F

ImmunityBio has requested an urgent meeting with the FDA after receiving a Refusal to File (RTF) letter for its supplemental biologics license application (sBLA) for ANKTIVA in treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease. This RTF was surprising as the company had previously received unanimous encouragement from FDA leadership to submit the application. The inconsistency raises concerns about the regulatory framework and impact on patients awaiting treatment options. ImmunityBio remains dedicated to resolving the issue swiftly to avoid jeopardizing patient care.

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

ImmunityBio, Inc. has executed a $75 million equity financing agreement with a single institutional investor to enhance its working capital and support ongoing operations. The agreement includes a registered direct offering of common stock and warrants, potentially yielding gross proceeds of up to $90 million if the warrants are fully exercised. The financing is subject to customary closing conditions and will be made available under the company's existing shelf registration. ImmunityBio focuses on developing next-generation therapies to bolster the immune system against cancers and infectious diseases.

Mar 31, 2025

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA to Treat Lymphopenia Company to Provide Regulatory, Sales, and Platform Updates at Investor Day inc

ImmunityBio announced the submission of a supplemental Biologics License Application (sBLA) for ANKTIVA, aimed at treating non-muscle invasive bladder cancer in papillary disease. The company also submitted an Expanded Access Protocol (EAP) for ANKTIVA to treat lymphopenia. Recent financial results indicate a 129% increase in net product revenue and significant sales growth. The upcoming Investor Day is expected to provide further insights into ImmunityBio's platforms and ongoing studies.

ImmunityBio Reports Sales Momentum Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024 With a permanent J-code (J9028) awarded in January 2025, ImmunityBio's Februa

ImmunityBio reported strong sales momentum for its product ANKTIVA following the issuance of a permanent J-code in January 2025. February sales volume surged 97% compared to December 2024, contributing to a 21% quarter-over-quarter revenue increase. The FDA granted the company Regenerative Medicine Advanced Therapy designation for ANKTIVA, which may enhance its development prospects. Despite these gains, ImmunityBio faces challenges with rising operational costs and a continuing net loss.

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock CULVER CITY, Calif. (BUSINESS WIRE)

ImmunityBio, Inc. has announced the pricing of its underwritten public offering of 33,333,334 shares of common stock at $3.00 per share, aiming to raise around $100 million. The funds are expected to be used to further commercialization of its FDA-approved product ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer and to support ongoing clinical trials. The offering is set to close on or around December 12, 2024, subject to customary conditions. ImmunityBio continues to focus on advancing its immunotherapy platforms to enhance cancer treatment options.

Dec 10, 2024

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock CULVER CITY, Calif. (BUSINESS WIRE)

ImmunityBio, Inc. has announced a proposed public offering of its common stock, subject to market conditions. The company aims to use the proceeds for the commercialization of its immunotherapy ANKTIVA and to fund additional trials targeting non-muscle invasive bladder cancer and non-small cell lung cancer. The offering includes a 30-day option for underwriters to purchase additional shares. However, there is uncertainty regarding the eventual completion and terms of the offering due to market conditions.

ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100 th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months H

ImmunityBio announced that it has completed the enrollment of 100 patients in its QUILT 3.032 trial, evaluating ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC CIS). The trial reported a notable 71% complete response rate, with durable responses lasting up to 54 months. This important data will be submitted for marketing authorization to the European Medicines Agency in the fourth quarter of 2024. The findings are expected to bolster the therapeutic landscape for patients with limited treatment options.

ImmunityBio Reports Third-Quarter 2024 Financial Results

ImmunityBio, Inc. reported its financial performance for the third quarter of 2024, noting significant progress with its product ANKTIVA, which gained a permanent J-code for wider patient access. The company achieved net product revenue of approximately $6.0 million, a significant increase from the previous quarter, and is pursuing regulatory approvals for ANKTIVA in the UK and EU. Despite the positive sales milestones, ImmunityBio faced a net loss of $85.7 million, reflecting increased operational costs in research and administration. The company holds substantial liquidity, with cash and marketable securities totaling $130.4 million.

ImmunityBio Announces FDA Approval of ANKTIVA , First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Designated an FDA Breakthrough Therapy, the novel immunotherapy ANKTIVA activa

ImmunityBio has announced the FDA approval of ANKTIVA, a first-in-class IL-15 receptor agonist for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). ANKTIVA, designated as a Breakthrough Therapy, activates the patient's immune cells to enhance tumor response, exceeding established clinical benchmarks for durability. This novel therapy shows potential to significantly improve outcomes for NMIBC patients, offering an important non-surgical option. ANKTIVA is expected to be available in the U.S. by mid-May 2024.

Jan 2, 2024

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million Up to $300 million non-dilutive capital exchanged for royalty payme

ImmunityBio has announced a $320 million investment from Oberland Capital, with $210 million funded at closing. This financing will support the company's commercialization strategy and ongoing clinical trials, particularly focusing on the potential FDA approval of Anktiva for treating non-muscle invasive bladder cancer. The overall capital raised by ImmunityBio in 2023 totals $850 million, highlighting strong investor support despite the inherent risks associated with regulatory approvals.

Sep 11, 2023

▲ +19.4%on this news· ran to +31% by day 1

ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities Financing improves the company's balance sheet and provides $200 million of capital, as follows Exchang

ImmunityBio has announced a significant financing package totaling $470 million from its founder Dr. Patrick Soon-Shiong and Nant entities. This includes exchanging $270 million of debt for equity and securing $200 million in new convertible term debt, aimed at supporting the company's operational and pre-commercialization activities. The financing allows for the extension of current debt maturities to late 2024 and is seen as a strategic move to bolster the company's position ahead of an anticipated FDA approval for its bladder cancer treatment. The company remains focused on expanding clinical trials and leveraging its unique immunotherapy platforms.

Jul 20, 2023

▼ -6.8%on this news· ran to -17% by day 3

ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors

ImmunityBio, Inc. has announced the execution of a $40 million equity financing arrangement with institutional investors to enhance its working capital and support ongoing business operations. The financing includes a registered direct offering for common stock and warrants that could yield up to an additional $48 million if fully exercised. This funding is aimed at advancing ImmunityBio's clinical-stage immunotherapy and vaccine development and aligns with their broader strategies in cancer treatment and infectious diseases.

Feb 15, 2023

▼ -6.4%on this news· ran to -25% by day 3

ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors

ImmunityBio, Inc. announced the successful execution of a $50 million equity financing with multiple institutional investors, focusing on providing working capital and supporting its business operations. The financing involves a registered direct offering that includes common stock issuance and warrants for additional shares, potentially allowing for total gross proceeds up to $110 million. The transaction is subject to customary closing conditions, with Jefferies LLC serving as the exclusive placement agent.

ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor Financing transactions include approximately $50 million of equity financing from a single institutional investor, $50 million of debt fin

ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor CITY, Calif., December 12, 2022 ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and suppo

Nov 15, 2022

NASDAQ: IBRX Overview Presentation November 2022 11/14/22 1 Forward-Looking Statements This presentation and the accompanying verbal remarks contain forward-looking statements within the meaning of the Private Securities

Forward-Looking Statements This presentation and the accompanying verbal remarks contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding data from the clinical trials for certain of ImmunityBio's

ImmunityBio Completes Acquisition of Athenex s Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility 409,000 square foot, state-of-the-art facility expands capabilities for large-scale manufacture of vacc

ImmunityBio Completes Acquisition of Athenex s Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility 409,000 square foot, state-of-the-art facility expands capabilities for large-scale manufacture of vaccine and immunotherapy product candidates CULVER CITY, C

Jan 12, 2022

ImmunityBio Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness Over 400,000 square foot, state-of-the-art, finish-fill and lyop

Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness CULVER CITY, Calif., January 12, 2022 ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company ( ImmunityBio ), today announced th

Dec 20, 2021

IMMUNITYBIO ANNOUNCES COMPLETION OF $470 MILLION POST-MERGER FINANCING TO FUND LATE-STAGE CANCER CLINICAL TRIALS, PHASE 3 OF COVID T-CELL UNIVERSAL BOOST VACCINE TRIAL AND PROVIDES UPDATE ON BLADDER CANCER B

IMMUNITYBIO ANNOUNCES COMPLETION OF $470 MILLION POST-MERGER FINANCING TO FUND LATE-STAGE CANCER CLINICAL TRIALS, PHASE 3 OF COVID T-CELL UNIVERSAL BOOST VACCINE TRIAL AND PROVIDES UPDATE ON BLADDER CANCER BLA FILING CULVER CITY, Calif., December 20, 2021 - ImmunityBio, Inc. (N

Sep 13, 2021

ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cyste

ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial CULVER CITY, Calif., September 13, 2021 I

Jun 15, 2021

FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer Open-label Phase 1b/2 study will evaluate the safety and preliminary effica

FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer CULVER CITY, Calif., June 15, 2021 ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it has received FDA

Jun 4, 2021

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered

A Leading Immunotherapy Biotech Company Broad Late-Stage Clinical Platform of Antibody Cytokine Fusion Proteins, Albumin-Linked Chemo-Immunomodulators, Vaccine Vectors and Natural Killer cells NASDAQ:IBRX June 4, 2021 Exhibit 99.1 This presentation contains forward-looking sta

Apr 22, 2021

INDEX TO IMMUNITYBIO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Auditors 2 Consolidated Balance Sheets at

INDEX TO IMMUNITYBIO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Auditors 2 Consolidated Balance Sheets at December 31, 2020 and 2019 3 Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2020 and 2019 4 Cons

Apr 1, 2021

ImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of Directors

ImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of Directors CULVER CITY, Calif., April 1, 2021 ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced the appointment of health innovation expert and executive Linda Maxwe

Mar 10, 2021

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are considere

A Leading Immunotherapy Biotech Company Broadest Late-Stage Clinical Platform of Antibody Cytokine Fusion Proteins, Albumin-Linked Chemo-Immunomodulators, Vaccine Vectors and Natural Killer cells NASDAQ:IBRX Exhibit 99.1 This press release contains forward-looking statements w

Mar 9, 2021

ImmunityBio and NantKwest Complete Merger Creates Leading Immunotherapy and Cell Therapy Company CULVER CITY &

ImmunityBio and NantKwest Complete Merger Creates Leading Immunotherapy and Cell Therapy Company CULVER CITY & EL SEGUNDO, Calif., March 9, 2021 ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK) today announced the completion of their previously announced 100% stock-for-stock

Feb 24, 2021

ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors

ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors CULVER CITY, Calif., February 24, 2021 ImmunityBio, Inc., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and Wesley Cl

Jan 13, 2021

This presentation contains forward-looking statements relating to the proposed transaction involving NantKwest, Inc. ("NantKwest") and ImmunityBio, Inc. ("ImmunityBio"), including financial estimates and statements as to

39th Annual JP Morgan Healthcare Conference January 13, 2021 Exhibit 99.1 This presentation contains forward-looking statements relating to the proposed transaction involving NantKwest, Inc. ("NantKwest") and ImmunityBio, Inc. ("ImmunityBio"), including financial estimates and

Dec 21, 2020

IMMUNITYBIO AND NANTKWEST TO MERGE, CREATING A LEADING IMMUNOTHERAPY AND CELL THERAPY COMPANY Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immun

IMMUNITYBIO AND NANTKWEST TO MERGE, CREATING A LEADING IMMUNOTHERAPY AND CELL THERAPY COMPANY CULVER CITY, Calif. & EL SEGUNDO, Calif., December 21, 2020 ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cel

Oct 26, 2020

NantKwest Names Richard Adcock Chief Executive Officer Experienced Six Sigma healthcare executive bolsters leadership team at key juncture; will work closely with Dr. Patrick Soon-Shiong who will serve as Executive Chair

NantKwest Names Richard Adcock Chief Executive Officer Experienced Six Sigma healthcare executive bolsters leadership team at key juncture; will work closely with Dr. Patrick Soon-Shiong who will serve as Executive Chairman EL SEGUNDO, Calif., October 26, 2020 NantKwest, Inc.

Jun 24, 2020

BUSINESS The following summary highlights selected information about us. This summary is not complete and does not contain all the information that you should consider before investing in our common stock. Before making

The following summary highlights selected information about us. This summary is not complete and does not contain all the information that you should consider before investing in our common stock. Before making an investment decision, you should carefully read the section titled

Jun 10, 2019

JOHNSON FISTEL, LLP Frank J. Johnson (SBN 174882) 655 West Broadway, Suite 1400 San Diego, CA 92101 Telephone: (619) 230-0063 Facsimile: (619) 255-1856 Email: frankj@johnsonfistel.com Attorneys for Plaintiffs [Additional

Frank J. Johnson (SBN 174882) 655 West Broadway, Suite 1400 Telephone: (619) 230-0063 Facsimile: (619) 255-1856 Email: frankj@johnsonfistel.com Attorneys for Plaintiffs [Additional Counsel appear on signature page] SUPERIOR COURT OF THE STATE OF CALIFORNIA NOTICE OF PENDE

Jun 6, 2019

CHERYL COHEN APPOINTED TO NANTKWEST S BOARD OF DIRECTORS Culver City, CA

CHERYL COHEN APPOINTED TO NANTKWEST S BOARD OF DIRECTORS Culver City, CA, June 6, 2019 - NantKwest (Nasdaq:NK) today announced the appointment of Cheryl L. Cohen to the Board of Directors of NantKwest, effective immediately. Cheryl is a proven business executive and highly ex

Nov 17, 2015